Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 9/20 | 0.61 |
| ▸ | EDNRA | P25101 | 6/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314856 | 0.86 | EDNRB (0.52) | EDNRBEDNRAKDM4EMEN1LMNA | |
| SCHEMBL6313759 | 0.84 | EDNRB (0.62) | EDNRBEDNRATP53PPARGKDM4E | |
| SCHEMBL6315758 | 0.83 | EDNRB (0.61) | EDNRBEDNRATP53PPARGKDM4E | |
| SCHEMBL8553492 | 0.83 | EDNRB (0.64) | EDNRBEDNRATP53PPARG | |
| SCHEMBL8551194 | 0.83 | EDNRB (0.64) | EDNRBEDNRATP53POLB | |
| SCHEMBL8547579 | 0.81 | EDNRB (0.64) | EDNRBEDNRAMEN1NPC1KMT2A | |
| SCHEMBL8548527 | 0.81 | EDNRB (0.73) | EDNRBEDNRATP53POLB | |
| SCHEMBL8550228 | 0.81 | EDNRB (0.85) | EDNRBEDNRA | |
| SCHEMBL8553006 | 0.79 | EDNRB (0.62) | EDNRBEDNRAKDM4EHPGDHSD17B10 | |
| SCHEMBL8550885 | 0.79 | EDNRB (0.74) | EDNRBEDNRATP53MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885TP53 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.